Methods of cancer treatment
AssigneeCambridge Enterprise Limited
InventorsArthur Kaser, Zaeem Cader
Life of this patent
Estimating the term…
Loading patent…
AssigneeCambridge Enterprise Limited
InventorsArthur Kaser, Zaeem Cader
Estimating the term…
This invention relates to the finding that inhibition or inactivation of FAMIN (‘fatty acid metabolism-immunity nexus’; C13orf31; LACC1 (laccase domain containing 1)) reduces tumourigenesis and stimulates cell-mediated immune responses. Method of treating cancer or stimulating cell-mediated immune responses in an individual by reducing FAMIN activity in the individual are provided. Also provided are methods of activating T cells in vitro using FAMIN deficient immune cells and stimulating cell-mediated immune responses comprising administering (a) a population of FAMIN deficient immune cells; or (b) a population of T cells activated in vitro by a population of FAMIN deficient immune cells.
A method of treating cancer in an individual in need thereof comprising reducing FAMIN activity in the individual.
A method of stimulating a cell-mediated immune response in an individual in need thereof comprising reducing FAMIN activity in the individual.
A method according to any one of the preceding claims wherein the method comprises administering an agent which reduces FAMIN activity to the individual.
A method of stimulating cell-mediated immune responses comprising administering to an individual in need thereof;
An in vitro method of activating T cells comprising;
A pharmaceutical composition comprising a population of FAMIN deficient immune cells and/or a population of T cells activated by FAMIN deficient immune cells.
Dependencies are inferred from the claim text.